PTC Therapeutics, Inc. (PTCT) fair value analysis
Nasdaq · Updated 2026-10-19
PTCT price how computed
Valuation status
Awaiting full valuationPTCT does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $59.24
- Sector
- Healthcare
- 12-month range
- $59.24–$89.55
- Market cap
- $4.94B
- From 52-week high
- -33.8%
- Shares outstanding
- 83.5M
- Rank in Healthcare by quality score
- #87 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
PTC Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes medicines for rare genetic disorders and oncology. The company operates globally with a focus on bringing treatments to patients in North America, Europe, and other international markets.
PTCT currently ranks #87 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $4.94B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.01B
- Net margin
- -3.8%
- EPS (TTM)
- $-0.72
- Gross margin
- 94.5%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 27.8%
- Shares outstanding
- 83.5M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $67.49
- 200-day average
- $71.41
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+641.2%)
2026-03 ▲ beat (+93.2%)
2025-12 ▼ miss (-350.0%)
2025-09 ▲ beat (+117.1%)
2025-06 ▲ beat (+22.4%)
2025-03 ▲ beat (+1534.3%)
2024-12 ▲ beat (+47.4%)
2024-09 ▲ beat (+18.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 1 hold · 1 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $97.9
- Target vs last price
- +65.3%
What our data shows for PTCT
- Our model validated 4 trailing price-to-earnings windows for PTCT, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $59.24–$89.55.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PTCT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PTCT news
TickrTrends' derived news-sentiment signal for PTCT is currently leaning positive, computed from recent coverage.
- Truist Resumes Coverage on PTC Therapeutics (PTCT) with Hold, Citing Growth Concerns (gurufocus.com, 2026-10-16)
- PTCT Maintained by Cantor Fitzgerald -- Price Target Raised to $137 (gurufocus.com, 2026-09-22)
- PTC Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript (gurufocus.com, 2026-09-15)
More PTCT news
- PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com, 2026-09-15)
What people are saying
Follow the PTCT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for PTCT showed notable shifts this week. The quality grade declined from A to C, while the relative strength index zone moved from oversold to neutral territory. The current valuation verdict remains awaiting full valuation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for PTCT showed a shift in the Relative Strength Index zone this week, moving from neutral to oversold territory. The company's valuation verdict remains awaiting full valuation as of this update.
- 2026-09-21 — TickrTrends' derived indicators for PTCT show a shift in the 50/200-day trend state from mixed to downtrend this week. The current valuation verdict remains awaiting full valuation.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PTCT stock undervalued?
PTCT does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is PTCT's TickrTrends verdict?
PTCT is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does PTCT compare to other Healthcare stocks?
PTCT ranks #87 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PTCT overbought or oversold?
PTCT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PTCT report earnings next?
PTCT's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does PTCT usually beat earnings estimates?
Over its last 8 reported quarters PTCT beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PTCT?
Of 14 analysts covering PTCT, 12 rate it a buy, 1 a hold and 1 a sell - buy-leaning, with a consensus price target of $97.9 (+65.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.